Evaluation of the effect of zinc supplementation (Zn) in patients receiving methadone maintenance treatment

The effect of zinc supplementation (Zn) on metabolic profile and expression of IL10, PPAR?, NRF2 genes in methadone maintenance patients

Status

Recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT20200708048050N1

Enrollment

Registered

2020-09-08

Start date

2020-02-19

Completion date

Unknown

Last updated

2020-10-06

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

addiction. ???? ????? ?????? ??????

Interventions

Intervention 1: Intervention group: 30 mg International Zinc Supplement (Jalinous), orally daily for 12 weeks. Intervention 2: Control group: Placebo (Jalinous), every day of the week, orally for 12 w

Eligibility

Sex/Gender

All

Age

30 Years to 60 Years

Inclusion criteria

Inclusion criteria: Patients treated with methadone maintenance in the age range of 30 to 60 years

Exclusion criteria

Exclusion criteria: Positive urinary test for morphine, methamphetamine and cannabis Do not have a specific disease Zinc consumption in the last 3 months High blood pressure Consumption of psychiatric and neurological drugs during the study Digestive problems and side effects of zinc consumption Consumption of iron supplements

Design outcomes

Primary

Measure	Time frame
Anxiety. Timepoint: At the beginning of the study and 12 weeks after the intervention. Method of measurement: Beck Depression Inventory.;Depression. Timepoint: At the beginning of the study and 12 weeks after the intervention. Method of measurement: Beck Depression Inventory.	—

Secondary

Measure	Time frame
Total serum cholesterol. Timepoint: At the beginning of the study and 12 weeks after the intervention. Method of measurement: Clinical laboratory kit.;HDL-C Serum. Timepoint: At the beginning of the study and 12 weeks after the intervention. Method of measurement: Clinical laboratory kit.;Serum triglyceride. Timepoint: At the beginning of the study and 12 weeks after the interventio. Method of measurement: Clinical laboratory kit.;Fasting blood sugar. Timepoint: At the beginning of the study and 12 weeks after the interventio. Method of measurement: Enzymatic.;Insulin. Timepoint: At the beginning of the study and 12 weeks after the interventio. Method of measurement: Eliza.;Insulin sensitivity. Timepoint: At the beginning of the study and 12 weeks after the interventio. Method of measurement: Formula calculation.;Insulin resistance. Timepoint: At the beginning of the study and 12 weeks after the interventio. Method of measurement: Formula calculation.;Total Glutathione. Timepoint: At the beginning of the study and 12 weeks after the interventio. Method of measurement: Spectrophotometry.;Malone di aldehyde. Timepoint: At the beginning of the study and 12 weeks after the interventio. Method of measurement: Spectrophotometry.;Expressed levels of PPAR-?. Timepoint: At the beginning of the study and 12 weeks after the intervention. Method of measurement: PCR.;Expressed levels of IL-10. Timepoint: At the beginning of the study and 12 weeks after the intervention. Method of measurement: PCR.;Expressed levels of NRF2. Timepoint: At the beginning of the study and 12 weeks after the intervention. Method of measurement: PCR.	—

Measure

Time frame

Total serum cholesterol. Timepoint: At the beginning of the study and 12 weeks after the intervention. Method of measurement: Clinical laboratory kit.;HDL-C Serum. Timepoint: At the beginning of the study and 12 weeks after the intervention. Method of measurement: Clinical laboratory kit.;Serum triglyceride. Timepoint: At the beginning of the study and 12 weeks after the interventio. Method of measurement: Clinical laboratory kit.;Fasting blood sugar. Timepoint: At the beginning of the study and 12 weeks after the interventio. Method of measurement: Enzymatic.;Insulin. Timepoint: At the beginning of the study and 12 weeks after the interventio. Method of measurement: Eliza.;Insulin sensitivity. Timepoint: At the beginning of the study and 12 weeks after the interventio. Method of measurement: Formula calculation.;Insulin resistance. Timepoint: At the beginning of the study and 12 weeks after the interventio. Method of measurement: Formula calculation.;Total Glutathione. Timepoint: At the beginning of the study and 12 weeks after the interventio. Method of measurement: Spectrophotometry.;Malone di aldehyde. Timepoint: At the beginning of the study and 12 weeks after the interventio. Method of measurement: Spectrophotometry.;Expressed levels of PPAR-?. Timepoint: At the beginning of the study and 12 weeks after the intervention. Method of measurement: PCR.;Expressed levels of IL-10. Timepoint: At the beginning of the study and 12 weeks after the intervention. Method of measurement: PCR.;Expressed levels of NRF2. Timepoint: At the beginning of the study and 12 weeks after the intervention. Method of measurement: PCR.

—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactAzam Ghasemi Nejad

Kashan University of Medical Sciences

samiraghasemineghad@gmail.com+98 31 7504687

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026